Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | FLT3 | P36888 | 7/20 | 1.00 |
| ▸ | QPCT | Q16769 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.60 |
| ▸ | PRKACG | P22612 | 1/20 | 0.60 |
| ▸ | PRKACB | P22694 | 1/20 | 0.60 |
| ▸ | CCND1 | P24385 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607875 | 0.94 | KDR (1.00) | GSK3BKDRFLT3QPCTCDK4 | |
| SCHEMBL12507153 | 0.90 | KDR (1.00) | GSK3BKDRFLT3 | |
| SCHEMBL12507154 | 0.89 | KDR (0.85) | GSK3BKDRFLT3QPCTCDK4 | |
| SCHEMBL12607357 | 0.89 | GSK3B (1.00) | GSK3BKDRFLT3 | |
| SCHEMBL12506833 | 0.89 | FLT3 (1.00) | GSK3BKDRFLT3CDK4PRKACA | |
| SCHEMBL17067823 | 0.88 | GSK3B (0.78) | GSK3BKDRFLT3QPCTPRKACA | |
| SCHEMBL19090336 | 0.88 | GSK3B (0.78) | GSK3BKDRFLT3QPCT | |
| SCHEMBL12506836 | 0.86 | GSK3B (1.00) | GSK3BKDRFLT3QPCTPRKACA | |
| SCHEMBL14671146 | 0.86 | GSK3B (1.00) | GSK3BKDRFLT3QPCT | |
| SCHEMBL9954914 | 0.85 | GSK3B (0.87) | GSK3BKDRFLT3QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045449-B2 | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2021-06-29 | — | — | US | disclosed |
| US-20200253930-A1 | 3-(5-Fluoroindolyl)-4-arylmaleimide Compounds and their Use in Tumor Treatment | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3397632-B1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2020-06-24 | — | — | EP | disclosed |
| WO-2017114863-A1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2017-07-06 | — | — | WO | disclosed |
| EP-2655359-B1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9364459-B2 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2512469-B1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2513089-B1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-9012659-B2 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-04-21 | — | — | US | disclosed |
| US-8957103-B2 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg—Universitat Mainz (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-12-26 | — | — | US | disclosed |
| EP-2655359-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2474541-A1 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes- Gutenberg-Universität Mainz (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012084683-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073092-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073091-A1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029986-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | SI, AADAC, INMT | GSK3B 1739/4885KDR 3330/4885FLT3 3961/4885 |
| US-20200253930-A1 | 3-(5-Fluoroindolyl)-4-arylmaleimide Compounds and their Use in Tumor Treatment | FLT4, GSK3B, FLT1 | GSK3B 2/4885KDR 5/4885FLT3 6/4885 |
| US-20130131060-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, INMT, IDH1 | GSK3B 3234/4885KDR 1067/4885FLT3 431/4885 |
| US-20130345281-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | IDH3A, IDH1, INMT | GSK3B 3094/4885KDR 861/4885FLT3 997/4885 |
| US-11045449-B2 | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | FLT4, GSK3B, FLT1 | GSK3B 2/4885KDR 5/4885FLT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.